Serious neonatal morbidity or perinatal death · third trimester induction of labour in women with a viable fetus
Balloon (Foley or ATAD) showed no clear difference in serious neonatal morbidity or perinatal death compared with low‐dose oral misoprostol (low certainty).
1 finding from 1 review
Serious maternal morbidity or death · third trimester induction of labour in women with a viable fetus
It is very uncertain whether balloon (Foley or ATAD) changes serious maternal morbidity or death compared with low‐dose oral misoprostol (very low certainty).
1 finding from 1 review
Apgar score less than 7 at 5 minutes · third trimester induction of labour in women with a viable fetus
Balloon (Foley or ATAD) showed no clear difference in apgar score < 7 after 5 minutes compared with low‐dose oral misoprostol (low certainty).
1 finding from 1 review
Admission to neonatal intensive care unit · third trimester induction of labour in women with a viable fetus
Balloon (Foley or ATAD) showed no clear difference in neonatal intensive care unit admission compared with low‐dose oral misoprostol (low certainty).
1 finding from 1 review
Vaginal delivery not achieved within 24 hours · third trimester induction of labour in women with a viable fetus
Balloon (Foley or ATAD) showed no clear difference in vaginal delivery not achieved in 24 hours compared with low‐dose vaginal misoprostol (low certainty).
1 finding from 1 review
Uterine hyperstimulation with fetal heart rate changes · third trimester induction of labour in women with a viable fetus
Balloon (Foley or ATAD) probably leads to lower uterine hyperstimulation with FHR changes compared with low‐dose vaginal misoprostol (moderate certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · active EoE pediatric patients
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
Oral viscous budesonide showed no clear difference in histological improvement at study endpoint (dichotomous) compared with swallowed fluticasone (low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review